Enrolling by invitationPhase 3NCT06859099
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
Studying Chronic inflammatory demyelinating polyneuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Intervention
- Riliprubart Prefilled Pen (PFP)(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (30)
- Alabama Neurology Associates- Site Number : 8400019, Homewood, Alabama, United States
- University of Kansas Medical Center- Site Number : 8400010, Kansas City, Kansas, United States
- Investigational Site Number : 0320003, Buenos Aires, Argentina
- Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760004, Ribeirão Preto, São Paulo, Brazil
- Investigational Site Number : 1240001, Gatineau, Quebec, Canada
- Investigational Site Number : 1240002, Québec, Quebec, Canada
- Investigational Site Number : 1520003, Lo Barnechea, Reg Metropolitana de Santiago, Chile
- Investigational Site Number : 1520002, Santiago, Reg Metropolitana de Santiago, Chile
- Investigational Site Number : 1560013, Beijing, China
- Investigational Site Number : 1560005, Beijing, China
- Investigational Site Number : 1560011, Chengdu, China
- Investigational Site Number : 1560002, Fuzhou, China
- Investigational Site Number : 1560001, Shanghai, China
- Investigational Site Number : 1560003, Wuhan, China
- Investigational Site Number : 1560006, Wuhan, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06859099 on ClinicalTrials.govOther trials for Chronic inflammatory demyelinating polyneuropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07540221A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyGrifols Therapeutics LLC
- RECRUITINGPHASE3NCT06752356A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Kedrion S.p.A.
- RECRUITINGNCT07273903Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart DevicesHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE3NCT07091630A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPargenx
- ENROLLING BY INVITATIONPHASE2NCT07188844An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunovant Sciences GmbH
- RECRUITINGNCT07154524Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)University of Ulm
- RECRUITINGPHASE3NCT06920004A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPargenx
- RECRUITINGNCT07264426Real-World Efgartigimod Effectiveness in CIDP: A Prospective Studyargenx
See all trials for Chronic inflammatory demyelinating polyneuropathy →